What are the appropriate estrogen and progesterone doses for a woman with a uterus experiencing moderate to severe hot flashes?

Hormone Therapy Dosing for Moderate to Severe Hot Flashes in Women with a Uterus

For women with a uterus experiencing moderate to severe hot flashes, start with oral estradiol 0.5–1 mg or transdermal estradiol 25–50 µg daily, combined with micronized progesterone 200 mg orally for 12–14 days per month (sequential regimen) or 100 mg daily continuously. 1, 2

Estrogen Dosing

Start with the lowest effective dose to control symptoms while minimizing adverse effects. 1

Oral Estrogen Options:

• Micronized 17β-estradiol: 0.5–1 mg daily 1
• Conjugated equine estrogens: 0.3–0.625 mg daily 1
• Ethinyl estradiol: 0.01–0.02 mg daily 1

Transdermal Estrogen Options:

• Transdermal estradiol: 25–100 µg daily (patch changed twice weekly) 1
• Topical estradiol emulsion, gel, or spray 1

Prefer transdermal over oral estrogen in women with cardiovascular risk factors, as the transdermal route has more favorable effects on coagulation and thrombotic risk. 3

Progesterone Dosing (Mandatory for Endometrial Protection)

Women with an intact uterus must receive a progestogen to prevent endometrial hyperplasia and cancer from unopposed estrogen. 1

Sequential (Cyclic) Regimen:

• Micronized progesterone 200 mg orally daily for 12–14 days per month (minimum 10–12 days) 1, 2
• This produces predictable withdrawal bleeding 2–7 days after the last progesterone dose 4
• Preferred for most women due to lower breast cancer risk compared to synthetic progestins 2

Continuous Combined Regimen:

• Micronized progesterone 100 mg orally daily throughout the month 1, 2
• Achieves amenorrhea in most women after 6–12 months 4, 5
• Expect breakthrough bleeding during the first 6 months 4

Alternative Synthetic Progestins (if micronized progesterone unavailable):

• Medroxyprogesterone acetate: 2.5 mg daily continuous or 5 mg for 10–12 days/month 1
• Norethindrone acetate: 0.35 mg daily continuous or 5 mg for 10–12 days/month 1

Micronized progesterone is strongly preferred over synthetic progestins because it has lower cardiovascular risk, lower venous thromboembolism risk, and potentially lower breast cancer risk. 2, 3

Evidence-Based Combination Regimens

The REPLENISH trial (2018) demonstrated that estradiol 1 mg/progesterone 100 mg and estradiol 0.5 mg/progesterone 100 mg significantly reduced moderate-to-severe hot flash frequency and severity at weeks 4 and 12 versus placebo, with no endometrial hyperplasia observed. 6

• Estradiol 1 mg/progesterone 100 mg reduced hot flash frequency by 40.6 points at week 4 and 55.1 points at week 12 (vs 26.4 and 40.2 for placebo) 6
• Estradiol 0.5 mg/progesterone 100 mg reduced frequency by 35.1 points at week 4 and 53.7 points at week 12 6
• Both doses provided clinically meaningful improvements in symptom severity 7, 8

Route Selection Algorithm

1. First-line: Oral micronized progesterone 200 mg for 12–14 days/month + oral or transdermal estrogen 2
2. If oral progesterone causes intolerable sedation, bloating, or mood changes: Switch to vaginal micronized progesterone 200 mg daily for 12–14 days/month, which provides equivalent endometrial protection with fewer systemic side effects 2, 4
3. If patient has cardiovascular risk factors: Use transdermal estradiol 50 µg/day + micronized progesterone 4, 3
4. If patient desires amenorrhea: Use continuous combined regimen (transdermal estradiol 50 µg/day + oral micronized progesterone 100 mg daily), but counsel that amenorrhea requires 6–12 months 4

Critical Safety Considerations

Absolute contraindications to hormone therapy include: 3

• Current, past, or suspected breast cancer
• Estrogen-sensitive malignancies
• Active or recent venous thromboembolism (DVT/PE)
• Active or recent arterial thromboembolism (MI, angina)
• Active liver disease
• Undiagnosed vaginal bleeding
• Untreated endometrial hyperplasia

Before initiating therapy: 3

• Assess cardiovascular risk factors (lipid profile, smoking status, diabetes, family history)
• Counsel that smoking markedly increases cardiovascular and VTE risk with estrogen
• Advise aggressive smoking cessation

Initiate hormone therapy only in women younger than 60 years or within 10 years of menopause onset to achieve the most favorable benefit-risk balance. 3

Monitoring and Management

• Revisit the decision to continue hormone therapy at least annually, targeting the shortest duration consistent with treatment goals 9
• For persistent breakthrough bleeding after 3 months on continuous combined therapy: Perform transvaginal ultrasound; if endometrial thickness >5 mm, obtain endometrial biopsy to exclude hyperplasia or malignancy 4
• Do not use FSH levels to monitor adequacy of hormone therapy, as FSH remains elevated despite adequate tissue effects 1, 2
• Monitor lipid profile and cardiovascular risk factors annually 1, 4

Common Pitfalls to Avoid

• Never prescribe estrogen alone in women with a uterus—this causes endometrial hyperplasia and cancer 1
• Do not use sequential progesterone for fewer than 10 days per month—shorter durations increase endometrial cancer risk 2
• Avoid custom-compounded hormone preparations lacking FDA oversight, as they have not demonstrated validated endometrial protection 2, 4, 3
• Do not prescribe systemic hormone therapy solely for vulvovaginal symptoms—use low-dose vaginal estrogen instead 9, 3
• Do not delay endometrial evaluation when bleeding is heavy, prolonged (>7 days), or occurs after 6–12 months of amenorrhea 4